Abstract Tumor cell infiltration is a major mechanism of treatment escape in glioblastoma. Src is an intracellular tyrosine kinase that mediates tumor cell motility and invasiveness. We evaluated the efficacy and safety of bosutinib, a tyrosine kinase inhibitor that potently inhibits Src and Abl, in patients with recurrent glioblastoma. In this two-arm study, patients with histologically confirmed recurrent glioblastoma and B2 relapses, not previously treated with anti-vascular endothelial growth factor (VEGF) therapy, were administered oral bosutinib 400 mg daily. Arm A planned for 6 patients who were candidates for surgical resection to be given bosutinib for 7-9 days prior to resection. Arm B was a two-stage design phase 2 trial targeting 30 patients. The primary endpoint was progression-free survival at 6 months (PFS6) in Arm B. After 9 patients enrolled onto stage 1 of Arm B, 9 (100 %) patients progressed within 6 months. Therefore, the study met the pre-specified criteria for early closure and both Arms were closed. In Arm B, Median PFS was 7.71 weeks and median OS was 50 weeks. Best objective response was stable disease in one patient (11.1 %). Seven patients (77.8 %) had treatment-related AEs of any grade and 2 (22.2 %) were grade C3. Arm A was closed after 2 patients enrolled. Src activation was evident in all archival tumor samples. Bosutinib monotherapy does not appear to be effective in recurrent glioblastoma. However, Src remains a potential target based on its upregulation in tumor samples and role in glioma invasion.
Background
Patients with glioblastoma (GBM) have a poor prognosis. Despite treatment including maximal surgical resection, concurrent radiation and temozolomide and adjuvant temozolomide [1] , median progression-free survival (PFS) and overall survival (OS) remain 6.9 and 14.6 months, respectively, and 5-year survival is approximately 10 % [2] . Prognosis at recurrence is dismal and treatment options are limited [3, 4] . There is an urgent need to identify novel therapeutic targets for drug development.
GBMs are highly infiltrative tumors, making pathways involved in tumor cell motility and invasion rational targets. Src is an intracellular tyrosine kinase that coordinates multiple extracellular factors involved in cell-cell and cell-matrix adhesions. Upregulation of Src reduces these adhesions, promoting increased cell motility, invasion and metastatic potential [5, 6] . Activated Src is increased in several solid tumors, including several GBM cell lines and 61 % of GBM tumor specimens from first resection [7] . In pre-clinical GBM models, Src inhibition reduced cell proliferation and viability, and increased glioma cell apoptosis [7, 8] . Src might also play a role in glioma angiogenesis and inhibition in pre-clinical models reduced vessel density and vascular endothelial growth factor (VEGF)-induced vascular permeability [9, 10] . Therefore, Src is a potentially attractive therapeutic target in GBM.
Several clinical trials in GBM have investigated dasatinib-a potent Src inhibitor that also inhibits c-Kit, c-Fms, and platelet-derived growth factor receptor-b (PDGFR-b) [11] . However, phase 1 studies of dasatinib in combination with the nitrosourea lomustine (CCNU) [12] and epidermal growth factor receptor (EGFR) inhibitor erlotinib [13] , as well as a phase 2 trial of dasatinib monotherapy [14, 15] did not demonstrate efficacy. A retrospective study of dasatinib and bevacizumab also did not reveal a significant improvement in PFS or OS [16] .
Bosutinib is a potent third generation tyrosine kinase inhibitor (TKI) that dually targets Src and the oncogene Abl with IC 50 values for enzyme inhibition of 3.5 and 1 nM, respectively. It is approved for use in Philadelphia chromosome-positive chronic myelogenous leukemias (CML) with resistance or intolerance to first or second-generation TKIs [17, 18] . It differs from dasatinib in its specificity for Src and Bcr-Abl, while minimizing activity against c-KIT or PDGFR [19, 20] . Bosutinib is orally administered and well tolerated in CML patients with low-grade gastrointestinal toxicity reported most commonly [21] . Although bosutinib lacks brain penetration in animal models, a CSF penetrance of only 1 % (ratio of CSF to plasma concentrations) would achieve concentrations in the CSF that completely inhibit Src enzyme activity in vitro. The objective of this phase 2 study was to evaluate the efficacy and safety of bosutinib in patients with recurrent GBM.
Patients and methods

Patients
Eligible patients (aged C18 years) had histologically confirmed GBM (World Health Organization grade IV astrocytoma); had received temozolomide and radiation as firstline therapy; had B2 prior systemic treatments; had Karnofsky performance status (KPS) C60 %, and had archived tumor material available. In addition, recurrent GBM patients enrolled on Arm A were candidates for resection.
Key exclusion criteria included concomitant use of CYP3A4/5 inhibitors or potent inducers; clinically relevant gastrointestinal abnormalities; uncontrolled or significant cardiovascular disease within 6 months of registration; history of a different malignancy (unless disease-free for at least 3 years and deemed to be at low risk for recurrence of that malignancy). Individuals with cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin were eligible if diagnosed and treated within the past 3 years. Patients were not eligible if they had evidence of other malignancy requiring therapy other than surgery within the last 3 years. Patients previously treated with anti-VEGF directed therapy or alternating electric field therapy were excluded since the data regarding the efficacy of any therapy after progression on these modalities were lacking at the time of study initiation. Patients enrolled on Arm A were removed from study if their diagnostic pathology demonstrating only gliosis or necrosis without active tumor.
The Dana-Farber/Harvard Cancer Center institutional review board approved the study protocol. All procedures were performed in accordance with the ethical standards of the Helsinki Declaration. All patients provided written informed consent.
Study design
This open-labeled, dual-arm, single-agent, study of bosutinib (SKI-606) in patients with recurrent GBM was conducted at Massachusetts General Hospital Cancer Center and DanaFarber Cancer Institute (ClinicalTrials.gov: NCT01331291). There were two treatment arms. Patients enrolled on Arm A were candidates for resection with the exploratory outcome of measuring intratumoral Src phosphorylation. The target enrollment for Arm A was 6 patients. Arm B was designed as a Simon two stage, phase 2 trial with a target enrollment of 30 patients (see Statistical Analysis). The primary endpoint was progression-free survival at 6 months (PFS6).
Secondary analyses included adverse events (AEs), overall survival (OS), median progression-free survival (PFS), overall response rate (ORR) according to the Macdonald criteria, [22] and response duration. Exploratory endpoints included pharmacodynamic tumor response assessed by phosphorylated Src (pSrc) in Arm A.
Patients on Arm A received bosutinib 400 mg by mouth daily for 7-9 days prior to surgery. After at least 10 days had elapsed post-operatively, these subjects resumed bosutinib at 400 mg daily in 28-day cycles until disease progression, intolerability, or withdrawal of consent. Patients on Arm B received bosutinib 400 mg by mouth daily in 28-day cycles until disease progression, intolerability, or withdrawal of consent. Bosutinib 400 mg daily was the recommended phase 2 dose based on phase 1 data in patients with advanced solid tumors [23] .
Tumor assessments
For the secondary outcome of overall response rate, tumor response was assessed by Macdonald criteria [22] . Patients in both arms had a contrast-enhanced baseline MRI within 21 days of starting bosutinib. In Arm A, an MRI was conducted within 24-48 h post-surgery and again prior to reinitiating bosutinib. In both arms, tumors were assessed serially with MRI on every other cycle.
Safety
All AEs from the time of enrollment until the end of study were graded using the Cancer Therapy Evaluation Program (CTEP) Active Version of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). For both arms, clinical and basic laboratory assessments (hematology, blood chemistry, urinalysis, and coagulation studies) were performed at baseline, cycle 1/day 1, cycle 1/day 14, and day 1 of each subsequent cycle. In addition, patients on Arm A had clinical and laboratory assessments on day 1 pre-surgery and the day of surgery.
Pharmacodynamics
Src immunohistochemistry (IHC) of archival tumor samples was performed on paraffin slides. Slides were deparaffinized through xylene and dehydrated through ethanol. Heated EDTA buffer was used for antigen retrieval and slides were blocked with peroxidase for 5 min and 10 % normal goat serum/5 % milk/1 % bovine serum in trisbuffered saline with tween for 1 h at room temperature. Immunohistochemistry for phosphorylated Src was performed on archival tumor samples and post-treatment resection tumor specimens from the two patients who were enrolled on Arm A. Archival and post-treatment resection samples were collected as per standard procedure, fixed in formalin and embedded in paraffin. All H&E slides were reviewed with a neuropathologist (A.S.R.) and included viable tumor tissue. All archival and post-surgical slides were prepared and stained at the same time to eliminate batch effect. Slides were scored as noted above using pSrc primary antibody [pSrc (Tyr416) #2101, Cell Signaling]. Livers from human hepatocellular carcinoma xenografts were used as positive controls.
Statistical analysis
The study utilized a Simon two stage optimal trial design with PFS6 in Arm B as the primary outcome [24] . PFS6 was defined as the proportion of patients alive and progression-free at 6 months. PFS was calculated as the time in weeks from the first dose of bosutinib to disease progression (per Macdonald criteria) or death from any cause. In a pooled database of patients with recurrent GBM, the 6-month progression-free survival rate was determined to be 9 % [16] . If the true PFS6 in Arm B were 30 % or more, there would be interest in further investigation of bosutinib. Arm B tested the null hypothesis (H0) with 5 % significance level that the PFS6 was B9 % versus the alternative hypothesis (Ha) that the PFS6 was C30 %. The optimal Simon two-stage design that minimized expected sample size with 80 % power required that 10 subjects enroll in Stage I and that this arm of the study would terminate if 9 or 10 subjects experienced progression or death within 6 months. If 2 or more subjects were alive and progression free at 6 months, an additional 20 subjects were planned to be enrolled onto Stage II for a total of 30 subjects. If at the end of the trial, 25 or more total had experienced progression or death within 6 months, Ha would be rejected. The expected sample size was 14.5 and the probability of early termination was 0.775. If PFS6 is \9 %, there is a type I error rate of 0.034). If PFS6 [30 %, there is a 0.185 probability of concluding that the drug is not effective (81.5 % power). The primary and secondary endpoints and safety analyses were conducted for all patients who received C1 dose of bosutinib in each cohort. Kaplan-Meier was used to graphically depict the distributions of OS and PFS among patients with disease progression or death. Best ORR (complete, response, partial response, stable disease) was calculated as a proportion with 2-sided 95 % confidence interval (CI). Cox proportional hazards models were used to assess the relationship between time-to-event end points and baseline variables. GraphPad Prism software (GraphPad Software Inc, La Jolla, CA) was used for statistical analysis.
Results
Patients
Between August 2, 2011 and February 6, 2013, 11 patients were enrolled in this study-2 in Arm A and 9 in Arm B (Table 1 ). In the entire study, median age at enrollment was 52 (range 36-62), median KPS 90 (range 90-70). Seven (63.6 %) patients were male, and 9 (81.8 %) white. Seven (63.6 %) had gross total resections at diagnosis and 3 (27.3 %) subtotal resections. All patients received standard, initial therapy with temozolomide and radiation at diagnosis, and 1 (9.1 %) was also treated with an investigational intravenous radiation sensitizer PPX (CT-2103) concurrently with radiation. Median time from diagnosis to trial enrollment was 10 months (range 8.58-46.03).
For the entire study, median duration of treatment with bosutinib was 7.71 weeks (range 1.86-23.86) with median number of cycles of 2 (range 1-6). Median follow-up time was 23.57 weeks (range 2.57-63.71). The reason for discontinuing treatment was progression in 10 (90.9 %) patients and death due to disease progression in 1 (9.1 %) patient.
Efficacy
The primary endpoint of Arm B, a phase II trial, was progression-free survival at 6 months. After 9 patients were enrolled on Arm B, the interim analysis revealed that 9 (100 %) patients had disease progression including death in 1 (11.1 %) patient. Based on the Simon two stage design, this met the pre-specified criteria for study termination. Median PFS in Arm B from initiation of study treatment to date of progression was 7.71 weeks (95 % CI 2.6-7.9). Median OS from initiation of study treatment for patients on Arm B was 50 weeks (95 % CI 2.9-NA) (Fig. 1) . The best objective response in patients on Arm B was stable disease in one patient (11.1 %) and progressive disease in 8 (88.9 %). Specific treatment regimens after study discontinuation were not recorded.
Toxicity
In the entire study, all patients received bosutinib at a dose of 400 mg daily. Including both arms, 3 (27.3 %) patients experienced dose holds for a median of 2.5 days (range 2-5). One (9.1 %) patient was held for seizures, one (9.1 %) for grade 1/2 elevated transaminases, and one (9.1 %) for external ear pain. There were no dose reductions. The most common AE of any grade was lymphopenia in 9 (81.8 %), fatigue in 6 (54.6 %), and nausea in 6 (54.6 %) ( Table 2 ). Seven patients (63.6 %) had AEs of any grade considered related to treatment with bosutinib although only 2 (18.2 %) were grade C3.
Correlative analysis of tumor samples
Immunohistochemistry for Src and pSrc was performed on all diagnostic (archival) tumor samples and post-bosutinib resection specimen samples from 2 patients on Arm A and were scored independently by two observers (J.W.T. and A.S.R.). Eleven out of 11 (100 %) archival tumors had evidence of Src upregulation and activation, as Src staining was 3? or greater in all specimens and all specimens had at least 1? pSrc (Table 3 ; Fig. 2 ). At the time of study closure, only 2 patients had enrolled onto Arm A. For the two patients on Arm A, pSrc levels scored lower in the posttreatment tumor specimen in comparison to the paired archival specimen (Fig. 2) . In addition, the pSrc:total Src ratios decreased in the post-treatment recurrent specimens for both patients; patient X scored 3?:3? in the diagnostic specimen and 1?:3?in the resection specimen and patient Y scored 3?:4? in the diagnostic specimen and 2?:4? in the resection specimen.
Discussion
Although analysis of archival tumor specimens demonstrated upregulation and activation of Src in all tumors, bosutinib did not appear to have single-agent efficacy in patients with recurrent GBM. In arm B, there were no objective radiographic responses and no patient met the study's primary efficacy endpoint of PFS6 [25] at the interim analysis and, consequently, the study was terminated early after 9 patients were enrolled in Arm B and 2 patients enrolled on Arm A. Including both arms, the best radiographic response was stable disease, and the longest duration on study was 23 weeks. Bosutnib was well tolerated with only 2 (18.2 %) grade C3 AEs (lymphopenia and hypophosphatemia). Although our study did not identify efficacy for bosutinib monotherapy in recurrent GBM, Src may remain a rational therapeutic target. Our analysis of Src in diagnostic tumor specimens is consistent with previous clinical and preclinical reports suggesting Src is upregulated in GBM [7] . Additionally, Src is a known mediator of motility and invasion in GBM [8, 26] . Preclinical evidence also suggests that activation of Src family kinases may promote GBM invasion after anti-angiogenic therapy [27] . In mice bearing GBM orthotopic xenografts, dasatinib, a Src inhibitor, effectively blocked the increased invasion induced by bevacizumab [27] . It is unclear why bosutinib did not demonstrate significant efficacy in our trial. One possibility may be because in animal models there is no CNS penetration [28] . Because of the small sample size of post-treatment specimens, which limited our ability to generate statistical conclusions, intratumoral concentrations of bosutinib were not measured. We observed some evidence of on-target inhibition in the two post-treatment specimens, as the pSrc:total Src ratios were decreased compared to the paired diagnostic specimens. However, the activation status of Src in the recurrent GBM population is unknown, and it's possible that Src activation is decreased in GBM tumors after standard chemoradiation. Analysis of Src activation in recurrent tumors warrants further investigation. In summary, our results suggest that bosutinib monotherapy is not associated with antitumor activity in recurrent GBM patients. We confirmed Src upregulation and activation in pre-treatment GBM tumors. Our correlative findings, along with the role of Src in glioma cell invasion, suggest Src warrants continued investigation as a target for therapy. Therapeutic efficacy may be realized in combination with other therapies, such as anti-angiogenic agents.
